Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of results from a Phase II trial (NCT03929666) assessing zanidatamab, an anti-HER2 pleotropic bispecific antibody, with chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma. Patients received the investigational therapy and a diarrheal prophalxis with a choice of FOLFOX, or capecitabine with cisplatin. A high response rate was reported, with a duration of response over 20 months. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.